Embecta

EMBC

Market cap $801M

ELAN, DINO and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 6, 2025.

CZNC, EMBC and FFBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 15, 2025.

RNGR, LRN, BWA, KT and EMBC have been added to the Zacks Rank #1 (Strong Buy) List on September 15, 2025.

JXN, EMBC and KT made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 9, 2025.

Embecta's restructuring and discontinuation of the patch pump system have significantly improved profitability, enabling substantial cost savings and debt reduction. The company is refocusing on core strengths, expanding into drug delivery and chronic care, and leveraging new pharma partnerships for broader growth. Financial guidance shows strong adjusted EPS and EBITDA margin growth, with cost-cutting driving earnings gains despite modest revenue declines.

EMBC's strong Q3 results and improved profitability highlight management's effective cost controls, despite revenue growth being driven by one-off events. The new strategic direction focuses on strengthening the core insulin delivery business and expanding into adjacent markets while aggressively deleveraging. Short-term revenue headwinds persist due to a shrinking core market, but EMBC's reputation and distribution network position it well for future adjacent market growth.

PARSIPPANY, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:

Embecta Corp. (EMBC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, EMBC broke through the 200-day moving average, which suggests a long-term bullish trend.

The consensus price target hints at a 25.7% upside potential for Embecta Corp. (EMBC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Embecta Corp. (NASDAQ:EMBC ) Q3 2025 Earnings Conference Call August 8, 2025 8:00 AM ET Company Participants Devdatt Kurdikar - President, CEO & Director Jacob P. Elguicze - Senior VP & CFO Pravesh Khandelwal - VP & Head of Investor Relations Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Gracia Leydon Mahoney - BofA Securities, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Michael K.